Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783026 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 123
- Enrollment target
NCT03783026 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 123 participants.
The verdict
NCT03783026, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 123 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy of apremilast, either in monotherapy or with stable methotrexate, on imaging outcomes in adults with active psoriatic arthritis with less than 5 years of disease duration (since diagnosis), and who are naïve to biologic therapies.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2022-05-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03783026
The ClinicalTrials.gov registry entry for NCT03783026 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT03783026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03783026 about?
NCT03783026 is a clinical study titled "A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis". This study is designed to assess the efficacy of apremilast, either in monotherapy or with stable methotrexate, on imaging outcomes in adults with active psoriatic arthritis with less than 5 years of disease duration (since diagnosis), and who are naïve to biologic therapies.
What is the current status of trial NCT03783026?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 123 participants. The study started on 2019-02-06. Estimated completion is 2022-05-11.
What interventions are being tested in trial NCT03783026?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT03783026?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.